Toxicity Assessment of Nanosilver Wound Dressing in Wistar Rat
Antibiotic resistance to microorganisms is one of the major problems faced in the field of wound care in burns patients. Silver nanoparticles have come up as potent antimicrobial agent and are being evaluated in diverse medical applications ranging from silver based dressings to silver coated medical devices. We aimed in present study to test the release of nanosilver from nanosilver wound dressing and compare the dermal and systemic toxicity of nanosilver dressings in a repeated dose (21 days) model. Under general anesthesia, a limited standard 2nd degree burns were provided on the back of each rat in all treatment, negative control (simple dressing) and 5% silver nitrate groups, each contained 5 male wistar rats. According to the analysis made by atomic absorption spectrometry, the wound dressings released 0.599 ± 0.083 ppm of nanosilver during first 24 hrs of study. Daily observations were recoded and wounds were covered with new dressings each 24 hrs. Burn healing was observed in nanosilver wound dressing group in shorter time periods than the control groups. In toxicity assessment, this dressing didn't cause any hematological and histopathological abnormalities in treatment group but biochemical studies showed significant rise of plasma transaminase (ALT) at the endpoint (21 days) of the study (P=0.027). Portal mononuclear lymphoid and polymorphonuclear leukocyte infiltrations in three to four adjacent foci were recognized around the central hepatic vein in treatment group. Mild hepatotoxic effects of nanosilver wound dressing in wistar rat emphasize the necessity of more studies on toxicity potentials of low dose nanosilver by dermal applications.
Costanza J, El Badawy AM, Tolaymat TM. Comment on “120 Years of Nanosilver History: Implications for PolicyMakers” .Environ Sci Technol 2011;45(17):7591-2.
Park SH, J-H Im JH, Im JW, Chun BH, Kim JH. Adsorption Kinetics of Au and Ag Nanoparticles on Functionalized Glass Surfaces. Microchemical Journal 1999;63(1):71-91. http://www.sciencedirect.com/science/article/pii/S0026265X99917691
Soni I, Salopek-Bondi B. Silver nanoparticles as antimicrobial agent: a case study on E.coli as a model for Gram-negative bacteria. J.Colloid Interface Science 2004;275(1):1770-82.
Crosera M, Bovenzi M, Maina G, Adami G, Zanette C, Florio C, Filon Larese F. Nanoparticle dermal absorption and toxicity: a review of the literature. : Int Arch Occup Environ Health 2009;82(9):1043-55.
Teodoro JS, Simões AM, Duarte FV, Rolo AP, Murdoch RC, Hussain SM, Palmeira CM. Assessment of the toxicity of silver nanoparticles in vitro: A mitochondrial perspective. Toxicol In Vitro 2011;25(3):664-705.
Monteiro DR, Gorup LF, Takamiya AS, Ruvollo-Filho AC, de Camargo ER, Barbosa DB. The growing importance of materials that prevent microbial adhesion: antimicrobial effect of medical devices containing silver. Int J Antimicrob Agents 2009;34(2):103-10.
M Korani, SM Rezayat, B Minaee, Arbabi Bidgoli S, Gilani K, Adeli S .Acute and subchronic dermal toxicity of nanosilver in guinea pig. Int J Nanomedicine 2011;6:855-62.
Poon VK, Burd A. In vitro cytotoxity of silver: implication for Clinical wound care. Burns 2004;30(2):140–7.
Paddle-Ledinek JE, Nasa Z, Cleland HJ. Effect of different Wound dressings on cell viability and proliferation. Plast Reconstr Surg 2006;117(7 Supple):110S–8S.
Cuttle L, Naidu S, Mill J, Hoskins W, Das K, Kimble RM. A retrospective cohort study of Acticoat versus Silvazine in a pediatric population.Burns 2007;33(6):701-7.
Benn T, Cavanagh B, Hristovski K, Posner JD, Westerhoff P. The release of nanosilver from consumer products used in the home. J Environ Qual 2010;39(6):1875-82.
National Research Council (US) Committee on Guidelines for the Use of Animals in Neuroscience and Behavioral Research. Guidelines for the Care and Use of Mammals in Neuroscience and Behavioral Research, Washington (DC): National Academies Press (US); 2003.
Fraser JF, Bodman J, Sturgess R,Faoagali J, Kimble RM. An inviro study of the anti-micribial efficacy of a 1% silver sulphadiazine and 0.2% chlorhexidine digluconate cream,1% silver sulphadiazine cream and a silver coated dressing.Burns 2004;30(1):35-41.
Siver S, Phung LeT, Silver G. Silver as biocides in burn and wound dressings and bacterial resistance to silver compounds. Microbial biotechnol 2006;33(7):627-34.
Geranio L, Heuberger M, Nowack B. The behavior ofsilver nanotextiles during washing. Environmental Science & Technology 2009;43(21):8113–8.
Stebounova LV, Adamcakova-Dodd A, Kim JS, Park H, O'Shaughnessy PT, Grassian VH, Thorne PS. Nanosilver induces minimal lung toxicity or inflammation in a subacute murine inhalation model. Part Fibre Toxicol 2011;8(1):5.
Hollinger MA. Toxicological aspects of topical silver pharmaceuticals. Crit Rev Toxicol 1996;26(3):255–60.
Tang J, Xi T. Status of biological evaluation on silver nanoparticles. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 2008;25(4):958-61.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.